Literature DB >> 2996553

Role of uridine phosphorylase in the anabolism of 5-fluorouracil.

P M Schwartz, R D Moir, C M Hyde, P J Turek, R E Handschumacher.   

Abstract

The activities of enzymes responsible for activating 5-fluorouracil (FUra) to 5-fluorouridine-5'-monophosphate (FUMP) were compared in normal and tumor tissues of rodents to assess the potential capacity of uridine phosphorylase to anabolize FUra to the nucleoside in the presence of ribose-1-phosphate (R-1-P). The activity of the alternative pathway to FUMP with a pyrimidine phosphoribosyltransferase [FUra + 1-pyrophosphoribosyl-5-phosphate (PPRP)] was approximately 15 to 17 nmoles/mg protein/hr in bone marrow from mice and rats and ranged from 28 to 47 nmoles/mg protein/hr in tumor tissues. Uridine phosphorylase [measured as the formation of 5-fluorouridine (FUrd) from FUra and R-1-P] was 35-230 nmoles/mg/hr in bone marrow and in two FUra-sensitive solid tumors, colon tumor No. 38 in mice and RPMI colon tumor in rats; the activity of uridine phosphorylase from L5178Y ascites leukemic cells was notably lower, 8 nmoles/mg/hr. Levels of uridine kinase ranged from 55 to 187 nmoles/mg protein/hr. Thus, the activities of the enzymes of the two-step FUra activating pathway were high compared to the PPRP-dependent activity in all tissues except L5178Y; also, the FUra-sensitive tumors yielded extracts with 1.5 to 6.5 times greater enzyme activity than the corresponding activity in bone marrow. Uridine phosphorylase was partially purified from rat liver, RPMI rat tumor and colon tumor No. 38; the apparent Km of FUra averaged 50 microM, almost 9-fold lower than that of uracil, and the apparent Km of R-1-P for condensation with FUra was 33 microM. The tissue concentration of R-1-P was greater than 70 microM in kidney and liver of rodents and somewhat less in spleen. Colon tumor No. 38 and RPMI colon tumor had 12 and 20 microM R-1-P, respectively, but these low values may reflect low tumor viability. The high levels of uridine phosphorylase and uridine kinase activities in normal tissues and even higher levels in tissues from FUra-sensitive tumors, as well as the sufficient concentration of R-1-P relative to its kinetic constant, suggest that FUra metabolism by the two-step pathway to FUMP may be a significant factor in the activity and selectivity of FUra.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996553     DOI: 10.1016/0006-2952(85)90737-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

2.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

3.  Expression, purification, crystallization and preliminary X-ray structure analysis of Vibrio cholerae uridine phosphorylase in complex with thymidine.

Authors:  Alexander A Lashkov; Azat G Gabdulkhakov; Igor I Prokofev; Tatyana A Seregina; Sergey E Sotnichenko; Andrey V Lyashenko; Alexander A Shtil; Alexander S Mironov; Christian Betzel; Al'bert M Mikhailov
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-10-30

Review 4.  Cancer stem cells and chemoresistance: The smartest survives the raid.

Authors:  Jihe Zhao
Journal:  Pharmacol Ther       Date:  2016-02-17       Impact factor: 12.310

Review 5.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

Review 6.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 7.  Cancer drug resistance: redox resetting renders a way.

Authors:  Yuan Liu; Qifu Li; Li Zhou; Na Xie; Edouard C Nice; Haiyuan Zhang; Canhua Huang; Yunlong Lei
Journal:  Oncotarget       Date:  2016-07-05

Review 8.  Emerging targets in cancer drug resistance.

Authors:  Shashank Kumar; Prem Prakash Kushwaha; Sanjay Gupta
Journal:  Cancer Drug Resist       Date:  2019-06-19

9.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.